Top Markets
#1 Akedo Akedo +59.31%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.07%
#4 Velvet Velvet +43.76%
#5 Black Phoenix Black Phoenix +34.55%
#6 Ο„emplar Ο„emplar +26.67%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.66%
#8 Bitway Bitway +18.26%
#9 Perle Perle +16.48%
#10 Cap Cap +16.47%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Altamira Therapeutics Ltd. Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd.

CYTO
Rank in Stocks #38206
Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new... Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.
Share Price
$0.3
Last synced: 2026-02-10
Market Cap
$1.13M
Change (1 day)
0.00%
Change (1 year)
328.57%
Country
BM
Trade Altamira Therapeutics Ltd. (CYTO)

Category

Healthcare
Revenue for Altamira Therapeutics Ltd. (CYTO)
Revenue in Aug 2026 TTM: 0
According to Altamira Therapeutics Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Altamira Therapeutics Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE